Physician profile
Youssef Josephson
NPI 1598928608
$496,335.52
in general payments reported to CMS, 2019-2025
58 companies · $20K in 2025
The $20K reported for 2025 was more than what 96% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $100K · 2021: $90K · 2022: $61K · 2023: $29K · 2024: $33K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Travel and Lodging: $11K · Consulting Fee: $6,125 · Entertainment: $136 · Education: $61.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,007.50 |
| Food and Beverage | $12,539.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,515.00 |
| Travel and Lodging | $10,877.44 |
| Consulting Fee | $6,125.00 |
| Entertainment | $135.74 |
| Education | $61.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $172,929.49 | 2019-2025 | Proclaim, Prodigy, Octrode |
| Boston Scientific Corporation | $121,169.32 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept Rf Probe |
| Vertiflex, INC. | $98,432.30 | 2019 | |
| Medtronic USA, INC. | $37,177.29 | 2019-2020 | |
| Painteq LLC | $22,356.78 | 2021-2024 | Painteq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $8,372.69 | 2019-2025 | Relistor |
| Tersera Therapeutics LLC | $7,397.03 | 2019-2025 | Prialt |
| Medtronic, INC. | $7,288.62 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Aurora Spine, INC. | $5,280.19 | 2022 | |
| Vertos Medical, INC. | $4,556.94 | 2019-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $2,564.67 | 2021-2023 | Intracept |
| Nalu Medical, INC. | $1,877.37 | 2020-2024 | Nalu Neurostimulation System |
| Biodelivery Sciences International, INC. | $761.13 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $718.15 | 2019-2025 | Xtampza, Belbuca |
| Nevro Corp. | $568.68 | 2019-2024 | Senza |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $565.96 | 2019-2025 | |
| Globus Medical, INC. | $457.81 | 2025 | Senza, Vyrsa V1, Vyrsa V1 |
| Horizon Therapeutics Plc | $453.18 | 2019-2022 | |
| Zyla Life Sciences, INC. | $426.72 | 2019-2020 | |
| Pfizer INC. | $300.51 | 2019-2021 | |
| Si-Bone, INC. | $269.46 | 2019-2025 | |
| Stimwave Technologies Incorporated | $223.90 | 2019-2021 | |
| Mdd US Operations, LLC | $220.17 | 2019-2020 | |
| Daiichi Sankyo INC. | $203.83 | 2019 | |
| Uswm, LLC | $139.69 | 2021-2022 | |
| Spinal Simplicity, LLC | $132.75 | 2020 | |
| Novo Nordisk INC | $110.37 | 2022 | |
| Biotronik Nro, INC. | $106.01 | 2024-2025 | Prospera |
| Bioventus LLC | $97.60 | 2019-2022 | |
| Spr Therapeutics, INC | $85.53 | 2019-2024 | Sprint Pns System |
| Arbor Pharmaceuticals, INC. | $84.47 | 2019-2020 | |
| Saluda Medical Americas, INC. | $75.58 | 2023-2025 | Evoke Scs, Evoke |
| Ibsa Pharma INC. | $73.48 | 2020-2023 | Tirosint, Licart |
| Scilex Pharmaceuticals INC. | $69.35 | 2019-2023 | Ztlido |
| Takeda Pharmaceuticals U.S.A., INC. | $67.83 | 2019 | |
| Protega Pharmaceutials INC | $65.44 | 2023-2024 | Roxybond |
| Flowonix Medical Incorporated | $60.84 | 2019 | |
| Avanos Medical | $52.31 | 2022-2023 | Trivisc Sodium Hyaluronate, Genvisc 850 Sodium Hyaluronate |
| Grt US Holding, INC. | $50.50 | 2020-2021 | |
| Brixton Biosciences, INC. | $47.91 | 2024 | Neural Ice |
| Depuy Synthes Sales INC. | $47.39 | 2019-2024 | Orthovisc, Monovisc |
| Axonics, INC. | $41.00 | 2021 | |
| Mml US, INC. | $36.35 | 2023 | Reactiv8 |
| International Rehabilitative Sciences, INC | $34.66 | 2024 | Rs 4i Plus Sequential Stimulator |
| Azurity Pharmaceuticals, INC. | $33.78 | 2023-2025 | Horizant, Horizant |
| Forte Bio-Pharma LLC | $33.19 | 2023-2024 | Prolate, Nalocet |
| Alexion Pharmaceuticals, INC. | $30.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $26.54 | 2019 | |
| Fidia Pharma USA INC. | $24.72 | 2024 | Triluron |
| Stryker Corporation | $23.27 | 2024 | Spinejack |
| Almatica Pharma LLC | $16.66 | 2023 | Loreev Xr, Gralise |
| Shionogi INC | $14.83 | 2019 | |
| Averitas Pharma INC. | $14.63 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $14.14 | 2024 | Onzetra Xsail |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2022 | |
| Redhill Biopharma INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$855.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Josephson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.